Acalabrutinib Plus Bendamustine-Rituximab in Untreated Mantle Cell Lymphoma.

Journal:

Journal of Clinical Oncology

Published:

2025-05-02

DOI:

10.1200/jco-25-00690

Affiliations:

22

Authors:

21

Go to article

Institutions	Authors	Share
AstraZeneca, United Kingdom (UK)	2.000000	0.10
AstraZeneca United States, United States of America (USA)	2.000000	0.10
University Hospital Brno, Czech Republic	1.000000	0.05
Beijing Cancer Hospital / School of Oncology, PKUHSC, China	1.000000	0.05
Henan Cancer Hospital, ZZU, China	1.000000	0.05
National Cancer Institute, Ukraine	1.000000	0.05
United Hospitals Villa Sofia-Cervello, Italy	1.000000	0.05
Cross Cancer Institute, AHS, Canada	1.000000	0.05
University Hospital of Munich (KUM), LMU, Germany	1.000000	0.05
Central Coast Haematology, Australia	1.000000	0.05
Mayo Clinic, United States of America (USA)	1.000000	0.05
Washington University in St. Louis (WUSTL), United States of America (USA)	1.000000	0.05
Pratia, Poland	1.000000	0.05
Hospital de Clínicas de Porto Alegre (HCPA), UFRGS, Brazil	1.000000	0.05
Germans Trias i Pujol University Hospital (HUGTP), ICS, Spain	1.000000	0.05
The University of Texas MD Anderson Cancer Center, United States of America (USA)	1.000000	0.05
Charles University (CU), Czech Republic	0.500000	0.02
University Hospital Hradec Králové, Czech Republic	0.500000	0.02
St Johns’ Oncology Center in Lublin (COZL), Poland	0.500000	0.02
Medical University of Lublin, Poland	0.500000	0.02
Sir Charles Gairdner Hospital (SCGH), Australia	0.500000	0.02
The University of Western Australia (UWA), Australia	0.500000	0.02

Interested in Cardiovascular Medicine and Haematology?